Rigel Pharmaceuticals (NasdaqGS:RIGL) - Share price, News & Analysis

RIGL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

RIGL Stock Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.

Rewards

Trading at 87% below our estimate of its fair value

Earnings are forecast to grow 70.5% per year

Risk Analysis

No risks detected for RIGL from our risk checks.

Rigel Pharmaceuticals Competitors

Amgen

NasdaqGS:AMGN

US$130.0b

Price History & Performance

Summary of all time highs, changes and price drops for Rigel Pharmaceuticals
Historical stock prices
Current Share Price	US$2.05
52 Week High	US$4.62
52 Week Low	US$1.80
Beta	1.48
1 Month Change	-30.98%
3 Month Change	-21.46%
1 Year Change	-44.29%
3 Year Change	0.49%
5 Year Change	-17.67%
Change since IPO	-96.80%

Recent News & Updates

Apr 21

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

	RIGL	US Biotechs	US Market
7D	4.1%	4.8%	0.7%
1Y	-44.3%	-22.0%	-10.8%

Return vs Industry: RIGL underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: RIGL underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is RIGL's price volatile compared to industry and market?
RIGL volatility
RIGL Average Weekly Movement	11.8%
Biotechs Industry Average Movement	12.3%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: RIGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: RIGL's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1996	165	Raul Rodriguez	https://www.rigel.com

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19.

Rigel Pharmaceuticals Fundamentals Summary

How do Rigel Pharmaceuticals's earnings and revenue compare to its market cap?
RIGL fundamental statistics
Market Cap	US$337.22m
Earnings (TTM)	-US$84.86m
Revenue (TTM)	US$77.45m

4.6x

P/S Ratio

-4.2x

P/E Ratio

Is RIGL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
RIGL income statement (TTM)
Revenue	US$77.45m
Cost of Revenue	US$64.77m
Gross Profit	US$12.68m
Other Expenses	US$97.54m
Earnings	-US$84.86m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.49
Gross Margin	16.37%
Net Profit Margin	-109.56%
Debt/Equity Ratio	1,309.9%

How did RIGL perform over the long term?

See historical performance and comparison

Valuation

Is Rigel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: RIGL ($2.05) is trading below our estimate of fair value ($15.74)

Significantly Below Fair Value: RIGL is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: RIGL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: RIGL is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RIGL's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: RIGL is overvalued based on its PB Ratio (51.9x) compared to the US Biotechs industry average (1.4x).

Future Growth

How is Rigel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

70.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RIGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: RIGL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RIGL's is expected to become profitable in the next 3 years.

Revenue vs Market: RIGL's revenue (31.2% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: RIGL's revenue (31.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RIGL's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Rigel Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

24.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RIGL is currently unprofitable.

Growing Profit Margin: RIGL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: RIGL is unprofitable, but has reduced losses over the past 5 years at a rate of 24.3% per year.

Accelerating Growth: Unable to compare RIGL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RIGL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: RIGL has a negative Return on Equity (-1248.29%), as it is currently unprofitable.

Financial Health

How is Rigel Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RIGL's short term assets ($138.9M) exceed its short term liabilities ($59.2M).

Long Term Liabilities: RIGL's short term assets ($138.9M) exceed its long term liabilities ($83.1M).

Debt to Equity History and Analysis

Debt Level: RIGL has more cash than its total debt.

Reducing Debt: Insufficient data to determine if RIGL's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RIGL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: RIGL has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 23.8% each year.

Dividend

What is Rigel Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RIGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RIGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RIGL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RIGL's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RIGL has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure

CEO

Raul Rodriguez (60 yo)

12yrs

Tenure

US$3,428,041

Compensation

Mr. Raul R. Rodriguez has been the Chief Executive Officer of Rigel Pharmaceuticals, Inc., since November 2014 and has been its President since May 2010. Mr. Rodriguez served as Chief Operating Officer at...

CEO Compensation Analysis

Compensation vs Market: Raul's total compensation ($USD3.43M) is about average for companies of similar size in the US market ($USD2.65M).

Compensation vs Earnings: Raul's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: RIGL's management team is considered experienced (4.8 years average tenure).

Board Members

Experienced Board: RIGL's board of directors are considered experienced (5.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/16 00:00
End of Day Share Price	2022/05/16 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31